Sanofi strengthens biosurgery offering with Pluromed acquisition
This article was originally published in Scrip
Executive Summary
Sanofi has agreed to buy surgical gel developer Pluromed for an undisclosed fee, bolstering the biosurgical portfolio it gained with its acquisition of Genzyme last year.